David Gallego‐Ortega

4.7k total citations · 2 hit papers
56 papers, 2.2k citations indexed

About

David Gallego‐Ortega is a scholar working on Molecular Biology, Oncology and Biomedical Engineering. According to data from OpenAlex, David Gallego‐Ortega has authored 56 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Molecular Biology, 22 papers in Oncology and 14 papers in Biomedical Engineering. Recurrent topics in David Gallego‐Ortega's work include Cancer Cells and Metastasis (12 papers), Single-cell and spatial transcriptomics (9 papers) and Microfluidic and Bio-sensing Technologies (7 papers). David Gallego‐Ortega is often cited by papers focused on Cancer Cells and Metastasis (12 papers), Single-cell and spatial transcriptomics (9 papers) and Microfluidic and Bio-sensing Technologies (7 papers). David Gallego‐Ortega collaborates with scholars based in Australia, Spain and United Kingdom. David Gallego‐Ortega's co-authors include Fátima Valdés‐Mora, Andrew M. K. Law, Juan Carlos Lacal, Christopher J. Ormandy, Ana Ramı́rez de Molina, Jacinto Sarmentero, Samantha R. Oakes, Guocheng Fang, Laura Rodríguez de la Fuente and Teresa Gómez del Pulgar and has published in prestigious journals such as Nature Communications, The Journal of Experimental Medicine and PLoS ONE.

In The Last Decade

David Gallego‐Ortega

55 papers receiving 2.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer

2020 346 citations Andrew M. K. Law, Fátima Valdés‐Mora et al. Cells profile →
Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment

2024 58 citations Thuỳ Anh Bùi, Rui Sang et al. EBioMedicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Gallego‐Ortega Australia	28	1.1k	775	445	426	301	56	2.2k
Célia Gomes Portugal	28	1.2k 1.1×	733 0.9×	434 1.0×	498 1.2×	287 1.0×	73	2.2k
Deepak Kanojia United States	22	773 0.7×	788 1.0×	292 0.7×	579 1.4×	238 0.8×	48	1.9k
Н. В. Чердынцева Russia	26	1.2k 1.1×	924 1.2×	751 1.7×	734 1.7×	232 0.8×	189	2.5k
Anca Maria Cîmpean Romania	24	1.2k 1.1×	1.0k 1.3×	563 1.3×	388 0.9×	184 0.6×	180	2.9k
Beihua Kong China	29	990 0.9×	523 0.7×	525 1.2×	409 1.0×	220 0.7×	99	2.3k
Shengyong Yin China	27	1.3k 1.2×	879 1.1×	603 1.4×	547 1.3×	272 0.9×	78	2.7k
Jumpei Kondo Japan	20	788 0.7×	723 0.9×	565 1.3×	201 0.5×	362 1.2×	78	1.9k
Judith H. Harmey Ireland	24	1.3k 1.2×	755 1.0×	641 1.4×	464 1.1×	257 0.9×	35	2.7k
Carol Box United Kingdom	20	778 0.7×	961 1.2×	315 0.7×	279 0.7×	481 1.6×	32	1.8k
Vladislava O. Melnikova United States	26	1.0k 0.9×	715 0.9×	522 1.2×	341 0.8×	375 1.2×	39	2.1k

Countries citing papers authored by David Gallego‐Ortega

Since Specialization

Citations

This map shows the geographic impact of David Gallego‐Ortega's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Gallego‐Ortega with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Gallego‐Ortega more than expected).

Fields of papers citing papers by David Gallego‐Ortega

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Gallego‐Ortega. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Gallego‐Ortega. The network helps show where David Gallego‐Ortega may publish in the future.

Co-authorship network of co-authors of David Gallego‐Ortega

This figure shows the co-authorship network connecting the top 25 collaborators of David Gallego‐Ortega. A scholar is included among the top collaborators of David Gallego‐Ortega based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Gallego‐Ortega. David Gallego‐Ortega is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhuang, Ling, Kenneth Lee, Sonja Klebe, et al.. (2025). A combination of PD-1 and TIGIT immune checkpoint inhibitors elicits a strong anti-tumour response in mesothelioma. Journal of Experimental & Clinical Cancer Research. 44(1). 51–51. 3 indexed citations

Salomon, Robert, et al.. (2025). Challenges in blood fractionation for cancer liquid biopsy: how can microfluidics assist?. Lab on a Chip. 25(5). 1097–1127. 1 indexed citations

Huang, Yin, Yijun Luo, Yuxia Luo, et al.. (2025). Lanthanide-doped nanoprobes for microRNA detection. Coordination Chemistry Reviews. 536. 216644–216644. 5 indexed citations

Chen, Hao, Matthew B. O’Rourke, Andrew J. Bannister, et al.. (2025). Matrix directs trophoblast differentiation in a bioprinted organoid model of early placental development. Nature Communications. 16(1). 8267–8267. 1 indexed citations

Bùi, Thuỳ Anh, et al.. (2024). Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment. EBioMedicine. 106. 105266–105266. 58 indexed citations breakdown →

Pertuz, Said, et al.. (2023). Saliency of breast lesions in breast cancer detection using artificial intelligence. Scientific Reports. 13(1). 20545–20545. 11 indexed citations

Ganguly, Debolina, Marcel O. Schmidt, Noah Sorrelle, et al.. (2023). Pleiotrophin drives a prometastatic immune niche in breast cancer. The Journal of Experimental Medicine. 220(5). 8 indexed citations

Yam, Andrew O., Jacqueline Bailey, Scott E. Youlten, et al.. (2023). Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy. Cancer Research. 83(8). 1315–1328. 21 indexed citations

Johansen, Matt D., Duc Hai Nguyen, Prabuddha S. Pathinayake, et al.. (2022). Increased SARS-CoV-2 Infection, Protease, and Inflammatory Responses in Chronic Obstructive Pulmonary Disease Primary Bronchial Epithelial Cells Defined with Single-Cell RNA Sequencing. American Journal of Respiratory and Critical Care Medicine. 206(6). 712–729. 31 indexed citations

10.

Piggin, Catherine, Daniel Roden, Andrew M. K. Law, et al.. (2020). ELF5 modulates the estrogen receptor cistrome in breast cancer. PLoS Genetics. 16(1). e1008531–e1008531. 16 indexed citations

11.

Law, Andrew M. K., Fátima Valdés‐Mora, & David Gallego‐Ortega. (2020). Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer. Cells. 9(3). 561–561. 346 indexed citations breakdown →

12.

Hassanzadeh‐Barforoushi, Amin, Majid Ebrahimi Warkiani, David Gallego‐Ortega, Guozhen Liu, & Tracie Barber. (2020). Capillary-assisted microfluidic biosensing platform captures single cell secretion dynamics in nanoliter compartments. Biosensors and Bioelectronics. 155. 112113–112113. 27 indexed citations

13.

Pinho, Andreia V., Lorraine A. Chantrill, David Herrmann, et al.. (2018). ROBO2 is a stroma suppressor gene in the pancreas and acts via TGF-β signalling. Nature Communications. 9(1). 5083–5083. 40 indexed citations

14.

Valdés‐Mora, Fátima, Kristina Handler, Andrew M. K. Law, et al.. (2018). Single-Cell Transcriptomics in Cancer Immunobiology: The Future of Precision Oncology. Frontiers in Immunology. 9. 2582–2582. 43 indexed citations

15.

Young, Adelaide I.J., Paul Timpson, David Gallego‐Ortega, Christopher J. Ormandy, & Samantha R. Oakes. (2017). Myeloid cell leukemia 1 (MCL-1), an unexpected modulator of protein kinase signaling during invasion. Cell Adhesion & Migration. 12(6). 513–523. 25 indexed citations

16.

Piggin, Catherine, Daniel Roden, David Gallego‐Ortega, et al.. (2016). ELF5 isoform expression is tissue-specific and significantly altered in cancer. Breast Cancer Research. 18(1). 4–4. 35 indexed citations

17.

Stone, Andrew, Mark J. Cowley, Fátima Valdés‐Mora, et al.. (2013). BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer. Molecular Cancer Therapeutics. 12(9). 1874–1885. 39 indexed citations

18.

Croucher, David R., Falko Hochgräfe, Luxi Zhang, et al.. (2013). Involvement of Lyn and the Atypical Kinase SgK269/PEAK1 in a Basal Breast Cancer Signaling Pathway. Cancer Research. 73(6). 1969–1980. 67 indexed citations

19.

Gallego‐Ortega, David, Teresa Gómez del Pulgar, Fátima Valdés‐Mora, Arancha Cebrián, & Juan Carlos Lacal. (2010). Involvement of human choline kinase alpha and beta in carcinogenesis: A different role in lipid metabolism and biological functions. Advances in Enzyme Regulation. 51(1). 183–194. 52 indexed citations

20.

Molina, Ana Ramı́rez de, David Gallego‐Ortega, Jacinto Sarmentero, et al.. (2008). Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: Implications in cancer therapy. The International Journal of Biochemistry & Cell Biology. 40(9). 1753–1763. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact